Omental adipose tissue containing a sarcoid-type granuloma (Hematoxylin and Eosin, ×10).

Omental adipose tissue containing a sarcoid-type granuloma (Hematoxylin and Eosin, ×10).

Source publication
Article
Full-text available
A rare case of ovarian sarcoidosis with peritoneal and omental involvement presenting as an ovarian malignancy is presented. Clinical, laboratory, and radiological evaluation of the patient revealed ascites and high levels of serum CA 125 and CA 15.3. The diagnosis of sarcoidosis was confirmed with pathology findings on tissues obtained during surg...

Similar publications

Article
Full-text available
Background: Tunneled peritoneal drainage catheters are described as an effective and relatively safe method in the management of malignant and non-malignant refractory ascites. Therapeutic advantages, linked to their use, are self-management of ascites and palliative care at home. Complications occur rarely. We describe an ascending colon perforat...

Citations

... After treatment, this patient's CA 15-3 level reduced but remained above the normal range. Other case reports showed elevated CA 15-3 levels due to ovarian sarcoidosis [10] or idiopathic pulmonary fibrosis [11] but did not report follow-up CA-15-3 values. ...
Article
Full-text available
Background Cancer antigen 15-3 is a protein that clinicians commonly measure to monitor outcomes and response to treatment in patients with breast cancer. However, cancer antigen 15-3 can also be elevated in other, benign and malignant conditions. Case presentation A 73-year-old White woman with history of breast cancer presented to her primary care physician with right hip pain, and laboratory testing revealed elevated cancer antigen 15-3. Further workup with radiographic imaging revealed a large mass in her right kidney. The renal mass was subsequently removed, and the cancer antigen 15-3 level returned to normal. Conclusions Elevation of cancer antigen 15-3 owing to causes other than breast cancer recurrence can be a potential diagnostic pitfall during a patient’s follow-up. It is important for clinicians to be aware of the limitations of cancer markers and to utilize a combination of diagnostic tests for patient evaluation.